Literature DB >> 27573781

Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future.

Rachel S van der Post1, Irene Gullo2,3,4, Carla Oliveira2,3, Laura H Tang5, Heike I Grabsch6, Maria O'Donovan7, Rebecca C Fitzgerald8, Han van Krieken1, Fátima Carneiro9,10,11.   

Abstract

Familial clustering is seen in 10 % of gastric cancer cases and approximately 1-3 % of gastric cancer arises in the setting of hereditary diffuse gastric cancer (HDGC). In families with HDGC, gastric cancer presents at young age. HDGC is predominantly caused by germline mutations in CDH1 and in a minority by mutations in other genes, including CTNNA1. Early stage HDGC is characterized by a few, up to dozens of intramucosal foci of signet ring cell carcinoma and its precursor lesions. These include in situ signet ring cell carcinoma and pagetoid spread of signet ring cells. Advanced HDGC presents as poorly cohesive/diffuse type carcinoma, normally with very few typical signet ring cells, and has a poor prognosis. Currently, it is unknown which factors drive the progression towards aggressive disease, but it is clear that most intramucosal lesions will not have such progression.Immunohistochemical profile of early and advanced HDGC is often characterized by abnormal E-cadherin immunoexpression, including absent or reduced membranous expression, as well as "dotted" or cytoplasmic expression. However, membranous expression of E-cadherin does not exclude HDGC. Intramucosal HDGC (pT1a) presents with an "indolent" phenotype, characterized by typical signet ring cells without immunoexpression of Ki-67 and p53, while advanced carcinomas (pT > 1) display an "aggressive" phenotype with pleomorphic cells, that are immunoreactive for Ki-67 and p53. These features show that the IHC profile is different between intramucosal and more advanced HDGC, providing evidence of phenotypic heterogeneity, and may help to define predictive biomarkers of progression from indolent to aggressive, widely invasive carcinomas.

Entities:  

Keywords:  CDH1; CTNNA1; E-cadherin; Gastric cancer; Hereditary; Immunohistochemistry; Signet-ring cell; Stomach

Mesh:

Substances:

Year:  2016        PMID: 27573781     DOI: 10.1007/978-3-319-41388-4_18

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  13 in total

Review 1.  Hereditary gastric cancer: what's new? Update 2013-2018.

Authors:  Rachel S van der Post; Carla Oliveira; Parry Guilford; Fátima Carneiro
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

2.  Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model.

Authors:  Kyoko Yamaguchi; Tomoyasu Yoshihiro; Hiroshi Ariyama; Mamoru Ito; Michitaka Nakano; Yuichiro Semba; Jumpei Nogami; Kenji Tsuchihashi; Takuji Yamauchi; Shohei Ueno; Taichi Isobe; Koji Shindo; Taiki Moriyama; Kenoki Ohuchida; Masafumi Nakamura; Yoshihiro Nagao; Tetsuo Ikeda; Makoto Hashizume; Hiroyuki Konomi; Takehiro Torisu; Takanari Kitazono; Tomohiro Kanayama; Hiroyuki Tomita; Yoshinao Oda; Hitoshi Kusaba; Takahiro Maeda; Koichi Akashi; Eishi Baba
Journal:  Gastric Cancer       Date:  2022-06-04       Impact factor: 7.701

3.  Indolent feature of Helicobacter pylori-uninfected intramucosal signet ring cell carcinomas with CDH1 mutations.

Authors:  Mitsuhiro Nikaido; Nobuyuki Kakiuchi; Shin'ichi Miyamoto; Tomonori Hirano; Yasuhide Takeuchi; Taro Funakoshi; Akira Yokoyama; Tatsuki Ogasawara; Yoshihiro Yamamoto; Atsushi Yamada; Takeshi Setoyama; Takahiro Shimizu; Yukari Kato; Suguru Uose; Takaki Sakurai; Sachiko Minamiguchi; Kazutaka Obama; Yoshiharu Sakai; Manabu Muto; Tsutomu Chiba; Seishi Ogawa; Hiroshi Seno
Journal:  Gastric Cancer       Date:  2021-05-07       Impact factor: 7.370

4.  Role of Δ133p53 isoform in NF-κB inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells.

Authors:  Hong-Mei Zhang; Xiao-Guang Sang; Yan-Ze Wang; Can Cui; Li Zhang; Wan-Sheng Ji
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

Review 5.  The evolving role of endoscopy in the diagnosis of premalignant gastric lesions.

Authors:  William Waddingham; David Graham; Matthew Banks; Marnix Jansen
Journal:  F1000Res       Date:  2018-06-08

Review 6.  Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review.

Authors:  Giovanni Corso; Giacomo Montagna; Joana Figueiredo; Carlo La Vecchia; Uberto Fumagalli Romario; Maria Sofia Fernandes; Susana Seixas; Franco Roviello; Cristina Trovato; Elena Guerini-Rocco; Nicola Fusco; Gabriella Pravettoni; Serena Petrocchi; Anna Rotili; Giulia Massari; Francesca Magnoni; Francesca De Lorenzi; Manuela Bottoni; Viviana Galimberti; João Miguel Sanches; Mariarosaria Calvello; Raquel Seruca; Bernardo Bonanni
Journal:  Cancers (Basel)       Date:  2020-06-17       Impact factor: 6.639

Review 7.  Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges.

Authors:  Yang Li; Zhikai Zhu; Fuhai Ma; Liyan Xue; Yantao Tian
Journal:  Cancer Manag Res       Date:  2020-09-03       Impact factor: 3.989

8.  Development of Triptolide Self-Microemulsifying Drug Delivery System and Its Anti-tumor Effect on Gastric Cancer Xenografts.

Authors:  Minghua Xie; Jia Wu; Liqaing Ji; Xiaorui Jiang; Jin Zhang; Min Ge; Xinjun Cai
Journal:  Front Oncol       Date:  2019-10-03       Impact factor: 6.244

Review 9.  Reprogramming of Mesothelial-Mesenchymal Transition in Chronic Peritoneal Diseases by Estrogen Receptor Modulation and TGF-β1 Inhibition.

Authors:  Robert B Wilson; Rami Archid; Marc A Reymond
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

10.  Increased risk for uterine cancer among first-degree relatives to Swedish gastric cancer patients.

Authors:  Johanna Samola Winnberg; Eva Rudd; Anne Keränen; Kristina Lagerstedt-Robinson; Annika Lindblom; Magnus Nilsson; Mats Lindblad; Krister Sjödahl
Journal:  Hered Cancer Clin Pract       Date:  2020-06-05       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.